An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

December 12, 2017

Primary Completion Date

June 30, 2031

Study Completion Date

June 30, 2031

Conditions
Achondroplasia
Interventions
DRUG

BMN 111

Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.

Trial Locations (24)

2145

The Children's Hospital at Westmead, Westmead

3052

Murdoch Children's Research Institute, Parkville

19803

Alfred I. duPont Hospital for Children, Wilmington

21287

Johns Hopkins University, Baltimore

29010

Hospital Universitario Virgen de la Victoria, Málaga

30322

Emory University, Atlanta

34752

Acibadem University School of Medicine, Istanbul

39120

Otto-von-Gericke Universitaet, Universitaetskinderklinik, Magdeburg

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

48149

Universitätsklinikum Münster, Münster

53226

Medical College of Wisconsin, Children's Hospital, Milwaukee

60611

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

65201

University of Missouri, Columbia

77030

Baylor College of Medicine, Houston

90509

Harbor - UCLA Medical Center, Torrance

94609

Children's Hospital & Research Center Oakland, Oakland

98105

Seattle Children's Hospital, Seattle

Unknown

Osaka University Hospital, Osaka

Saitama Children's Medical Center, Saitama

Tokushima University Hospital, Tokushima

08028

Institut Catala de Traumatologica I Medicina de l'Esport, Barcelona

08950

Hospital Sant Joan de Deu, Barcelona

SE1 9RT

Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital, London

S10 2TH

Sheffield Children's NHS Foundation Trust, Sheffield

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY